Volker Sandigj

Biography

EO of ProBioGen since June 14, 2010. Dr Wieland W. Wolf regards the positioning of ProBioGen as a leading, science driven contract partner for biopharmaceutical development and production within a network of strategic alliances and cooperations as his pre-eminent task. Special emphasis is put on the further exploration of the excellent scientific expertise and the unique technological know-how, to the benefit of ProBioGen's customers.  Looking back over three decades of biopharmaceutical experience, Wieland W. Wolf has held several positions in the biopharmaceutical industry. A biologist by education, he was involved in pioneering product registrations at Bioferon GmbH, headed a production unit for API and parenteral dosage forms at the same company, and was responsible for the biotechnology division of the Rentschler Group, which he led through its transformation from a product-oriented enterprise into an established service provider and contract manufacturing organization (CMO). He is the President of the European Association for Pharma Biotechnology and a member of the Board of Trustees of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB, Stuttgart, Germany).

Research Interest

EO of ProBioGen since June 14, 2010. Dr Wieland W. Wolf regards the positioning of ProBioGen as a leading, science driven contract partner for biopharmaceutical development and production within a network of strategic alliances and cooperations as his pre-eminent task. Special emphasis is put on the further exploration of the excellent scientific expertise and the unique technological know-how, to the benefit of ProBioGen's customers.  Looking back over three decades of biopharmaceutical experience, Wieland W. Wolf has held several positions in the biopharmaceutical industry. A biologist by education, he was involved in pioneering product registrations at Bioferon GmbH, headed a production unit for API and parenteral dosage forms at the same company, and was responsible for the biotechnology division of the Rentschler Group, which he led through its transformation from a product-oriented enterprise into an established service provider and contract manufacturing organization (CMO). He is the President of the European Association for Pharma Biotechnology and a member of the Board of Trustees of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB, Stuttgart, Germany).